文献速递肝病

组织学特征明确的非酒精性脂肪肝及脂肪性肝炎的全基因组关联研究

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆.
PubMed 文献 · J Hepatol · 2020-04-13

该GWAS纳入1,483例欧洲NAFLD病例和17,781例遗传匹配对照,并在559例病例和945例对照中复制。病例对照分析发现4个位点达全基因组显著性(GCKR/C2ORF16、HSD17B13、TM6SF2、PNPLA3),PNPLA3对脂肪变、纤维化和NAS均达全基因组显著性,PYGO1为新发现的脂肪变修饰位点。

要点

  • PNPLA3 rs738409对NAFLD全组织学谱达全基因组显著性,是核心风险位点。
  • TM6SF2和HSD17B13对NAFLD组织学谱有重要贡献,除GCKR/C2ORF16外均获复制。
  • PYGO1 rs62021874为脂肪变的新修饰位点,提示Wnt通路可能参与NAFLD发病。

核心结论

  • PNPLA3在全基因组显著性水平上被确认为NAFLD全组织学谱的风险因素,TM6SF2和HSD17B13亦有重要贡献。
  • PYGO1是新发现的脂肪变修饰基因,提示Wnt信号通路可能与NAFLD发病相关。

研究设计与样本

  • 研究为全基因组关联研究(GWAS),纳入1,483例欧洲NAFLD病例和17,781例遗传匹配对照。
  • 复制队列纳入559例NAFLD病例和945例对照,用于确认达全基因组或接近全基因组显著性的信号。

主要发现

  • 病例对照分析在4个位点发现p值≤5×10-8的信号:chr2 GCKR/C2ORF16、chr4 HSD17B13、chr19 TM6SF2、chr22 PNPLA3。
  • 另有两个信号p<1×10-7:chr1靠近LEPR和chr8靠近IDO2/TC1。
  • 仅病例的定量性状分析显示,PNPLA3 rs738409对脂肪变、纤维化和NAFLD活动度评分达全基因组显著性。
  • 新信号PYGO1 rs62021874对脂肪变接近全基因组显著性(p=8.2×10-8)。
  • NASH亚组病例对照分析确认PNPLA3信号,chr1 LEPR单核苷酸多态性对该表型亦达全基因组显著性。

临床怎么用

  • PNPLA3、TM6SF2和HSD17B13等位点的遗传信息可能有助于预测个体发生晚期NAFLD的风险。
  • PYGO1及Wnt信号通路相关基因可能成为未来NAFLD药物开发的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Genetic factors associated with non-alcoholic fatty liver disease (NAFLD) remain incompletely understood. To date, most genome-wide association studies (GWASs) have adopted radiologically assessed hepatic triglyceride content as the reference phenotype and so cannot address steatohepatitis or fibrosis. We describe a GWAS encompassing the full spectrum of histologically characterised NAFLD. METHODS: The GWAS involved 1,483 European NAFLD cases and 17,781 genetically matched controls. A replication cohort of 559 NAFLD cases and 945 controls was genotyped to confirm signals showing genome-wide or close to genome-wide significance. RESULTS: Case-control analysis identified signals showing p values ≤5 × 10-8 at 4 locations (chromosome [chr] 2 GCKR/C2ORF16; chr4 HSD17B13; chr19 TM6SF2; chr22 PNPLA3) together with 2 other signals with p <1 × 10-7 (chr1 near LEPR and chr8 near IDO2/TC1). Case-only analysis of quantitative traits showed that the PNPLA3 signal (rs738409) had genome-wide significance for steatosis, fibrosis and NAFLD activity score and a new signal (PYGO1 rs62021874) had close to genome-wide significance for steatosis (p = 8.2 × 10-8). Subgroup case-control analysis for NASH confirmed the PNPLA3 signal. The chr1 LEPR single nucleotide polymorphism also showed genome-wide significance for this phenotype. Considering the subgroup with advanced fibrosis (≥F3), the signals on chr2, chr19 and chr22 maintained their genome-wide significance. Except for GCKR/C2ORF16, the genome-wide significance signals were replicated. CONCLUSIONS: This study confirms PNPLA3 as a risk factor for the full histological spectrum of NAFLD at genome-wide significance levels, with important contributions from TM6SF2 and HSD17B13. PYGO1 is a novel steatosis modifier, suggesting that Wnt signalling pathways may be relevant in NAFLD pathogenesis. LAY SUMMARY: Non-alcoholic fatty liver disease is a common disease where excessive fat accumulates in the liver and may result in cirrhosis. To understand who is at risk of developing this disease and suffering liver damage, we undertook a genetic study to compare the genetic profiles of people suffering from fatty liver disease with genetic profiles seen in the general population. We found that particular sequences in 4 different areas of the human genome were seen at different frequencies in the fatty liver disease cases. These sequences may help predict an individual's risk of developing advanced disease. Some genes where these sequences are located may also be good targets for future drug treatments.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Anstee QM, Darlay R, Cockell S, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆. J Hepatol. 2020. PMID: 32298765. doi:10.1016/j.jhep.2020.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。